Pyrimidine Compounds as Gamma Secretase Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Alzheimer's disease, particularly those targeting Aβ42 production, often impair Notch signaling and have side effects due to non-specific inhibition of γ-secretase, which is crucial for various physiological processes.
Innovation Solution
Development of novel pyrimidine compounds that selectively inhibit Aβ40 and Aβ42 production while increasing Aβ37 and Aβ38 levels, maintaining Notch signaling integrity, with improved pharmacokinetic and pharmacodynamic profiles, including better absorption, faster onset of action, and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If γ-secretase is inhibited to reduce Aβ42 production, then Alzheimer's disease pathology is reduced, but Notch signaling is impaired causing toxic side effects
Solution Approach 1:
The patent applies local quality by designing compounds that selectively modulate γ-secretase activity toward specific substrates (Aβ peptides) while preserving activity toward other substrates (Notch receptors). This is achieved through allosteric modulation that creates substrate-specific effects, allowing Aβ42 reduction without compromising Notch signaling integrity.
Solution Approach 2:
The invention employs parameter changes by developing allosteric modulators that alter γ-secretase conformation and catalytic properties. These compounds change the enzyme's kinetic parameters and substrate affinity selectively, enabling preferential inhibition of Aβ42 production while maintaining normal Notch processing through differential kinetic effects on different substrates.
2Object-affected harmful factors
If non-specific γ-secretase inhibition is used to lower Aβ42, then Aβ pathology is reduced, but physiological functions dependent on γ-secretase are compromised
Solution Approach 1:
The patent implements local quality by creating compounds with selective substrate recognition properties. The allosteric modulators are designed to induce conformational changes in γ-secretase that specifically affect Aβ substrate processing while leaving Notch receptor processing unaffected, thereby achieving local selectivity in enzyme inhibition across different substrate types.
Solution Approach 2:
The invention uses an intermediary mechanism where allosteric modulators bind to a distinct site on γ-secretase away from the active site, inducing conformational changes that selectively affect substrate processing. This intermediary binding approach allows indirect control of enzyme activity with substrate-specific outcomes, avoiding direct competitive inhibition that would affect all substrates equally.
3Productivity
If conventional Aβ42 lowering strategies are employed, then therapeutic effect is achieved, but side effects increase due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing allosteric modulators that create localized effects on γ-secretase function. The compounds produce selective inhibition patterns where Aβ42 processing is suppressed while Notch signaling remains intact, achieving spatial and functional selectivity in enzyme modulation that reduces off-target side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The invention employs parameter changes through allosteric modulation that alters γ-secretase kinetic parameters selectively for different substrates. The modulators change enzyme affinity and catalytic rate constants in a substrate-dependent manner, enabling preferential reduction of Aβ42 production while preserving physiological functions that require normal γ-secretase activity.
Data Source
AI summary
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of Aβ-related diseases.